Skip to main content

VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS

 VALLOUREC AND SYNGULAR SOLUTIONS SIGN A MEMORANDUM OF UNDERSTANDING TO ACCELERATE THE DEVELOPMENT OF BIOENERGY WITH CARBON CAPTURE AND STORAGE PROJECTS Meudon (France), on May 22, 2026 – Vallourec, a world leader in premium seamless tubular solutions, announces the signing of a Memorandum of Understanding (MoU) with Syngular Solutions, Brazil’s leading engineering and consulting company specialized in Bioenergy with Carbon Capture and Storage (BECCS) and Carbon Capture Utilization and Storage (CCUS) projects, to collaborate on carbon capture and geological storage initiatives in Brazil. This agreement establishes a joint collaboration framework aimed at developing BECCS projects, a carbon removal technology that captures CO₂ from biomass-based energy systems and stores it permanently. This partnership with Syngular Solutions enables Vallourec...

Continue reading

Novo Announces Director Election Results

PERTH, Australia, May 21, 2026 (GLOBE NEWSWIRE) — Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) reports that all resolutions proposed to shareholders at the annual general meeting of shareholders (held on May 21, 2026 (Vancouver, BC)/May 22, 2026 (Perth, WA)) were approved, including the election of all of the director nominees listed in the management information circular for the meeting. Voting as to each of the director nominees was as follows:Name of Nominee Votes CastFOR % Votes CastFOR VotesWITHHELD % of VotesWITHHELDQuinton Hennigh 97,786,856 97.780 2,219,671 2.220Greg Jones 98,158,880 98.152 1,847,647 1.848Karen O’Neill 98,136,879 98.130 1,869,648 1.870Michael Spreadborough 97,354,477 97.348 2,652,050 2.652Refer to the report of voting results filed under Novo’s profile...

Continue reading

NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions, today announced the pricing of an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The common shares are being sold at a public offering price of US$2.50 per common share and accompanying warrant. Each accompanying warrant has an exercise price of US$3.68 per common share, and will be immediately exercisable from the date of issuance, and will expire five years from the date of issuance. All of the securities are being offered by NervGen. The securities...

Continue reading

Yimutian Inc. Announces Submission of Hearing Request to Nasdaq and Proactive Measures to Regain Full Compliance

BEIJING, May 21, 2026 (GLOBE NEWSWIRE) — Yimutian Inc. (Nasdaq: YMT) (“Yimutian” or the “Company”), a leading agricultural digital service company in China, today announced that it has formally submitted a hearing request to the Hering Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026, Eastern Time. As previously disclosed, on May 13, 2026, the Company received (i) a notification regarding its deficiency under the Minimum Market Value of Listed Securities (MVLS) requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A), and (ii) a Determination Letter notifying the Company of its non-compliance with the Minimum Market Value of Publicly Held Shares (MVPHS) requirement under Nasdaq Listing Rule 5450(b)(2)(C), and that it is subject to delisting. In response, the Company timely submitted the hearing request...

Continue reading

AIFA Provides Update on Nasdaq Notice and Filing of Annual Report, Clearing Key Pathways for Strategic Transformation

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance, Inc. (Nasdaq: AGAE) (the “Company” or “AIFA”) today provided an update regarding the previously received notice from the Listing Qualifications Department of The Nasdaq Stock Market. On May 19, 2026, the Company received a notice letter from Nasdaq (the “Notice Letter”) stating that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and had not yet completed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company was not in compliance with the timely filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) and therefore subject to delisting from Nasdaq Stock Market. The Company hereby informs all investors that the Company’s Annual Report on Form 10-K for the fiscal...

Continue reading

Medline Inc. announces pricing of upsized secondary offering of Class A common stock

NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) — Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the “Selling Stockholders”) at a price to the public of $37.00 per share. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 10,883,189 shares of Medline’s Class A common stock. The offering is expected to close on May 28, 2026, subject to customary closing conditions. Medline is not selling any shares of Class A common stock in the offering and will not receive any of the proceeds from the sale. Goldman...

Continue reading

Liminatus Pharma Announces Nasdaq Delisting Notification

FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) — Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“Nasdaq”). As previously disclosed in the Current Report on Form 8-K filed by the Company on November 25, 2025 with the Securities and Exchange Commission (the “SEC”), on November 19, 2025, the Company received notices from Nasdaq indicating that the Company’s listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Rule”) and the $15,000,000 market value of publicly held shares (MVPHS) requirement for continued listing in accordance with Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS...

Continue reading

Peyto Exploration & Development Corp. Announces Voting Results From Annual General Meeting of Shareholders

CALGARY, Alberta, May 21, 2026 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (TSX – PEY) (“Peyto“) is pleased to announce that the nominees listed in the information circular – proxy statement dated April 2, 2026 were elected as directors of Peyto at Peyto’s annual meeting of shareholders (the “Meeting“) held on May 21, 2026. The detailed results of the votes for the election of directors, the appointment of auditors and the advisory vote on executive compensation held at the Meeting are set out below. Election of Directors On a vote by ballot, each of the following nine nominees proposed by management was elected as a director of Peyto:Nominee   Outcome of Vote   Votes For   VotesWithheldDonald Gray   Elected   95,697,898   7,796,825Brian Davis   Elected   96,684,903   6,809,820Darren...

Continue reading

TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study

Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development  TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) — TaiMed Biologics (TPEX: 4147) today announced the completion of enrollment in its Phase 2b clinical study evaluating TMB-365/380, a novel investigational long-acting dual-antibody regimen for HIV maintenance therapy. The study reached Last Patient In (LPI) ahead of the planned schedule, marking an important operational milestone for the program. The Phase 2b study is designed to evaluate the efficacy and safety of TMB-365/380 as an every-two-month (Q2M), first-line HIV maintenance therapy for people living with HIV. With enrollment now complete, participants will continue scheduled follow-up, and TaiMed expects to report an interim analysis by year-end...

Continue reading

Rocket Lab Awarded $90M Contract to Build GEO Satellites Hosting Space Domain Awareness Payload for U.S. Space Force

Award marks Rocket Lab’s first satellite production program for geostationary orbit and continues a Space Systems Command program for development and delivery on orbit of two Heimdall prototype payloads by Rocket Lab Optical SystemsRocket Lab’s Lightning Spacecraft Production LineRocket Lab has been awarded a $90 million contract by the U.S. Space Force’s Space Systems Command (SSC) to design, manufacture, integrate, and operate two geostationary (GEO) satellites hosting the Heimdall space domain awareness (SDA) payload.LONG BEACH, Calif., May 21, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) a leading launch and space systems company, today announced it has been awarded a $90 million contract by the U.S. Space Force’s Space Systems Command (SSC) to design, manufacture, integrate,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.